Clinical trials: Normal Pregnancy
Breast Cancer, Cervical Cancer
Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer
RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above body temperature. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Breast Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00003135
- Testing
- fluorouracil, pegylated liposomal doxorubicin hydrochloride, hyperthermia treatment
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- The University of Texas Health Science Center, Houston
Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
Some tumors are difficult to treat with chemotherapy or radiation. One of the reasons is that areas of the tumor do not have many blood vessels, which makes it difficult for drugs to reach those areas.
- Conditions
- Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System, Malignant Neoplasms of Female Genital Organs
- Trial name
- NCT03435952
- Testing
- Pembrolizumab, Clostridium Novyi-NT, Doxycycline
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and gemcitabine hydrochloride in treating patients with folate receptor (FR) alpha-positive ovarian, primary peritoneal, fallopian tube…
- Conditions
- Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT02996825
- Testing
- Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- City of Hope Medical Center
Polycystic Ovary Syndrome, Infertility, Female
Feasibility Study of the AblaCare System in Transvaginal Ablation of Ovarian Tissue Under ULTRAsound Visualization in Women With Infertility Due to Polycystic Ovary Syndrome
The objective of the study is to provide preliminary evidence for the safety and effectiveness of the AblaCare System in transvaginal ablation of ovarian tissue under ultrasound visualization in women with infertility due to…
- Trial name
- ULTRA-US (NCT05320289)
- Testing
- AblaCare System
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- May Health
Herpes Simplex, Pregnancy
A Study of HSV Testing Among Pregnant Women
The objective of the study is to evaluate the acceptance and effect of type- specific HSV serologic testing of pregnant women on sexual behavior at the end of pregnancy.
- Trial name
- NCT00194415
- Testing
- Safer-sex counseling, Type specific serologic HSV testing
- Where
- Canada
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- University of Washington
Solid Tumor, Adult
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
- Trial name
- NCT05069935
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fate Therapeutics
SLE, Systemic Lupus Erythematosus (SLE)
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
This is a single-center, single-arm, open-label phase 1/2 study of CART19 in children and young adults with refractory Systemic lupus erythematosus (SLE), including both patients diagnosed with lupus nephritis (LN) and patients…
- Conditions
- SLE, Systemic Lupus Erythematosus (SLE), CAR T Cell, CART19
- Trial name
- NCT06839976
- Testing
- CART19
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Children's Hospital of Philadelphia
Breast Cancer, Renal Cell Carcinoma
Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study)
Everolimus shows a large interpatient variability with fixed dose administration. These very different exposure levels between individuals can result in supratherapeutic or subtherapeutic exposure levels and consequently in over…
- Trial name
- SPOT (NCT02809404)
- Testing
- Everolimus
- Where
- Netherlands
- Volunteers
- 75 people
- Sponsor
- Radboud University Medical Center
Lupus Nephritis
Human Umbilical Cord Mesenchymal Stem Cells Treatment for Lupus Nephritis (LN)
Lupus nephritis (LN) is one of the most serious complications and the main cause of death in patients with systemic lupus erythematosus (SLE).The investigators have investigated the usefulness, and confirmed the efficacy and…
- Trial name
- NCT03580291
- Testing
- Mesenchymal stem cells, Mycophenolate Mofetil
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Lingyun Sun
Acute Renal Failure
Augmented Vs. Normal Renal Replacement Therapy in Severe Acute Renal Failure (ARF).
This study seeks to determine if increasing the dose of continuous renal replacement therapy (CRRT) reduces 90-day all cause mortality in Intensive Care Unit (ICU) patients with severe acute renal failure (ARF).
- Trial name
- NCT00221013
- Testing
- "augmented" CRRT regimen
- Where
- Australia
- Volunteers
- 1,508 people
- Sponsor
- The George Institute
Lupus Nephritis, Type 1 Diabetes Mellitus
Autologous Adoptive T Regulatory Cell Transfer in Autoimmune Diseases.
Investigators aim to develop an effective and safe treatment of autoimmune diseases through adoptive T regulatory cells transfer.
- Trial name
- NCT05566977
- Testing
- autologous adoptive T regulatory cell transfer.
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Ain Shams University
Lupus Nephritis
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
This study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in participants with International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 class III or IV lupus…
- Trial name
- REGENCY (NCT04221477)
- Testing
- Obinutuzumab, MMF, Prednisone
- Where
- 74 sites in United States, Argentina and 13 more
- Volunteers
- 271 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer
Spatial Radiogenomics of Ovarian Cancer
The biological spatial and temporal heterogeneity of High Grade Serous Ovarian Carcinoma (HGSOC) severely impacts the effectiveness of therapies and is a determinant of poor outcomes.
- Trial name
- CO-MOULD (NCT06324175)
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Chronic Kidney Disease
A Research Study Looking Into Levels of the Medicine NNC0385-0434 in the Body and How Well it is Tolerated in Participants With Impaired Kidney Function Compared to Participants With Normal Kidney Function
Novo Nordisk is developing a new medicine, NNC0385-0434, to help people lower their cholesterol level. The aim of this study is to look at how NNC0385-0434 works in the body and how it is removed from the body in people with…
- Trial name
- NCT05094934
- Testing
- NNC0385-0434 A 100 mg
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Endometrial Cancer
Lymph Node Counts in Endometrial Cancer Staging
The purposes of this study are to determine whether total lymph node count or the percentage of identified nodes with metastatic disease are influenced by (1) the method of categorizing tissue specimens or (2) the techniques of…
- Trial name
- NCT02335775
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Duke University
brca1 Mutation Carrier, brca2 Mutation Carrier
Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
RATIONALE: rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and best dose of rucaparib and to see how well it works in…
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Ovarian Cancer
- Trial name
- NCT00664781
- Testing
- rucaparib (CO-338; formally AG-014699 or PF-01367338), protein expression analysis, western blotting
- Where
- 7 sites in United Kingdom
- Volunteers
- 78 people
- Sponsor
- Cancer Research UK
Lupus Nephritis
Identifying New Therapeutic Targets for Lupus Treatment
Lupus is an autoimmune disease affecting mainly young women (9/1). Lupus nephritis (LN) occurs in 30% of the cases of lupus and is associated with end stage renal disease (ESRD) in 17 to 25% of cases after 10 years.
- Trial name
- ELUDIAL (NCT03921398)
- Where
- France
- Volunteers
- 87 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Enuresis, Nocturnal, Ganglion
Ganglion Cell Thickness in Enuresis Nocturna
The precise role of the intrinsic circadian regulatory mechanism behind the pathogenesis of enuresis is not fully understood, but in theory, circadian rhythm irregularity may be the primary pathogenic mechanism not only for…
- Conditions
- Enuresis, Nocturnal, Ganglion, Circadian Rhythm Disorders
- Trial name
- NCT05126732
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Izmir Bakircay University
Colon Cancer, Gastric Cancer
Integrated Care Pathway in Oncology (PASSION)
A centralized unit for integrated management of care pathway in Oncology has been created. This unit settles the patients' appointments (biopsy, intravenous device, chemotherapy, imaging, oncologist...).
- Conditions
- Colon Cancer, Gastric Cancer, Pancreatic Cancer, Thoracic Neoplasms
- Trial name
- PASSION (NCT04235556)
- Testing
- Care pathway unit
- Where
- France
- Volunteers
- 1,800 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Participants With Moderate and Severe Renal Impairment and Healthy Participants
A Study to Investigate the Pharmacokinetics and Safety of PKN605 in Participants With Moderate and Severe Renal Impairment Compared to Matched Control Subjects With Normal Renal Function
The purpose of this trial is to assess any potential exposure increases of PKN605 in participants with reduced renal function to support decisions on participant eligibility and dosing in subsequent clinical trials of PKN605.
- Trial name
- NCT07797322
- Testing
- PKN605
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.